SCIENTIFIC PROGRAM
SUBSTRATES ANALYSIS AND RISK ASSESSMENT IN ARRHYTHMOGENIC CARDIOMYOPATHIES: THE ROLE OF CMR
Session 1 – Monday, December 14, 2020
Arrhythmic Mitral Valve Prolapse
INTRODUCTION: Focus on Mitral Valve Prolapse
S. Iliceto (Padua, Italy)
Morphological substrates of arrhythmias
M. Perazzolo Marra (Padua, Italy)
Role of cardiac imaging in the diagnosis
K. Haugaa (Oslo, Norway)
Arrhythmic risk stratification
F.N. Delling (San Francisco, USA)
State-of-the-art: Mitral Annular Disjunction
A.P.W. Lee (Hong Kong, China)
DISCUSSION
S. Iliceto (Padua, Italy) – Panelists
Session 2 – Tuesday, December 15, 2020
Focus on ACM
INTRODUCTION: Focus on ACM
B. Bauce (Padua, Italy)
Pathological hallmarks
G. Thiene (Padua, Italy)
CMR: When and Why?
V. Ferrari (Philadelphia, USA)
CMR and SCD Risk Assessment in ACM
A. Te Riele (Utrecht, The Netherlands)
State-of-the-art: Updated Diagnostic Criteria
D. Corrado (Padua, Italy)
DISCUSSION
B. Bauce (Padua, Italy) – Panelists
Session 3 – Monday, December 21, 2020
Dilated and Inflammatory Cardiac Disease
INTRODUCTION: Focus on Inflammatory Cardiac Disease
C. Bucciarelli Ducci (Bristol, United Kingdom)
Diagnosis? Endomyocardial Biopsy
A.L.P. Caforio (Padova, Italy)
Diagnosis? CMR is enough
V. Ferreira (Oxford, United Kingdom)
Prognostic value of tissue characterization
B. Halliday (London, United Kingdom)
State-of-the-art: Map to the future
M. Friedrich (Calgary, Canada)
DISCUSSION
C. Bucciarelli Ducci (Bristol, United Kingdom) – Panelists
Session 4 – Tuesday, December 22, 2020
Hypertrophic Cardiomyopathy
INTRODUCTION: Focus on Hypertrophic Cardiomyopathy
P. Elliott (London, United Kingdom)
CMR diagnostic features
M. Maron (Boston, USA)
Prognostic value of tissue characterization
S. Neubauer (Oxford, United Kingdom)
New techniques in CMR
D. Pennell (London, United Kingdom)
State-of-the-art: Arrhythmic risk stratification
W. McKenna (Doha, Qatar/London, United Kingdom)
DISCUSSION
P. Elliott (London, United Kingdom) – Panelists
Session 5 – Monday January 11, 2021
Rare Cardiomyopathies
INTRODUCTION: Focus on CMR in Rare Cardiomyopathies
J. Moon (London, United Kingdom)
CMR in muscular dystrophies
S. Mavrogeni (Athens, Greece)
CMR in Chagas cardiomyopathy
C.E. Rochitte (Sao Paulo, Brazil)
CMR in cardiac sarcoidosis
C. Shenoy (Minneapolis, USA)
State-of-the-art: CMR in cardiac amyloidosis
M. Fontana (London, United Kingdom)
DISCUSSION
J. Moon (London, United Kingdom) –Panelists
Session 6 – Tuesday January 12, 2021
Coronary Artery Disease
INTRODUCTION: Focus on CMR in coronary artery disease
S. Plein (Leeds, United Kingdom)
CMR in stress perfusion
R. Kwong (Boston, USA)
CMR in microvascular injury
C. Berry (Glasgow, United Kingdom)
CMR in MINOCA
C. Bucciarelli Ducci (Bristol, United Kingdom)
State-of-the-art: CMR and myocardial viability
P.G. Masci (London UK)
DISCUSSION
S. Plein (Leeds, United Kingdom) – Panelists
Session 7 – Monday January 18, 2021
Sport Activity and Arrhythmias
INTRODUCTION: Focus on CMR in SCD prevention in athletes
F. Migliore (Padua, Italy)
ECG and arrhythmic red flags
A. Zorzi (Padua, Italy)
The role of cardiac imaging in sport cardiology
M. Papadakis (London, UK)
The role of CMR in the risk assessment
A. La Gerche (Melbourne, Australia)
State-of-the-art: Risk stratification for sport activity in cardiomyopathies
A. Pelliccia (Rome, Italy)
DISCUSSION
F. Migliore (Padua, Italy) – Panelists
Session 8 – Tuesday January 19, 2021
Therapeutic Strategies
INTRODUCTION: primary prevention of sudden cardiac death in arrhythmogenic cardiomyopathies
G. Boriani (Modena, Italy)
Primary prevention of sudden cardiac death in non ischemic dilated cardiomyopathies
E. Bertaglia (Padua, Italy)
The right device in the right patient
Federico Migliore (Padua, Italy)
Long-term outcomes of ablation for ventricular arrhythmias in mitral valve prolapse
F.N. Delling (San Francisco, USA)
State-of-the-art: Electroanatomic mapping: from arrhytmogenic substrate to therapeutic ablation
P. Della Bella (Milan, Italy)
DISCUSSION
G. Boriani (Modena, Italy) – Panelists
Session 9 – Monday January 25, 2021
When and for Whom to Request CMR?
INTRODUCTION: the role of CMR in clinical practice
Z. Jing (Beijing, China) – S. Iliceto (Padua, Italy)
When in mitral valve prolapse?
R. Bonow (Chicago, USA)
When in ARVC?
D. Corrado (Padua, Italy)
When in cardiomyopathies?
R. Sukmawan (Jakarta, Indonesia)
When in coronary artery disease?
W. El Tahlawy (Abu Dhabi, United Arab Emirates)
When pathology is still essential?
C. Basso (Padua, Italy)
State-of-the-art: When echocardiography can avoid CMR?
L.P. Badano (Milan, Italy)
DISCUSSION
Z. Jing (Beijing, China)- S. Iliceto (Padua, Italy) – Panelists